Atrion (ATRI) vs. Its Competitors Financial Contrast
Atrion (NASDAQ: ATRI) is one of 81 publicly-traded companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it compare to its competitors? We will compare Atrion to related companies based on the strength of its dividends, analyst recommendations, earnings, risk, profitability, institutional ownership and valuation.
Insider & Institutional Ownership
59.0% of Atrion shares are held by institutional investors. Comparatively, 64.4% of shares of all “Medical Equipment, Supplies & Distribution” companies are held by institutional investors. 23.1% of Atrion shares are held by insiders. Comparatively, 12.2% of shares of all “Medical Equipment, Supplies & Distribution” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
This table compares Atrion and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent ratings and recommmendations for Atrion and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 4.85%. Given Atrion’s competitors higher probable upside, analysts clearly believe Atrion has less favorable growth aspects than its competitors.
Earnings and Valuation
This table compares Atrion and its competitors top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Atrion||$143.49 million||$27.58 million||32.37|
|Atrion Competitors||$975.11 million||$120.37 million||247.66|
Atrion’s competitors have higher revenue and earnings than Atrion. Atrion is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Atrion pays an annual dividend of $4.80 per share and has a dividend yield of 0.8%. Atrion pays out 26.6% of its earnings in the form of a dividend. As a group, “Medical Equipment, Supplies & Distribution” companies pay a dividend yield of 0.8% and pay out 36.2% of their earnings in the form of a dividend. Atrion has raised its dividend for 15 consecutive years.
Volatility and Risk
Atrion has a beta of 0.85, indicating that its stock price is 15% less volatile than the S&P 500. Comparatively, Atrion’s competitors have a beta of 0.94, indicating that their average stock price is 6% less volatile than the S&P 500.
Atrion competitors beat Atrion on 7 of the 12 factors compared.
Atrion Corporation (Atrion) is engaged in developing and manufacturing products, primarily for medical applications. The Company’s medical products range from fluid delivery devices to ophthalmic and cardiovascular products. Its fluid delivery products include valves that promote infection control and needle safety. It has developed a range of valves designed to fill, hold and release controlled amounts of fluids or gasses on demand for use in various intubation, intravenous, catheter and other applications in areas, such as anesthesia and oncology. Its cardiovascular product, MPS2 Myocardial Protection System (MPS2), is the system used in open-heart surgery that delivers fluids and medications, mixes critical drugs and controls temperature, pressure and other variables. The Company manufactures specialized medical devices that disinfect contact lenses. Its other medical and non-medical product lines consist of instrumentation and associated disposables.
Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.